about
Second-generation de novo design: a view from a medicinal chemist perspective.The antitumor histone deacetylase inhibitor suberoylanilide hydroxamic acid exhibits antiinflammatory properties via suppression of cytokines.Mycobacterium tuberculosis chaperonin 10 stimulates bone resorption: a potential contributory factor in Pott's disease.FTree query construction for virtual screening: a statistical analysis.Identifying the binding mode of a molecular scaffold.Prediction of kinase inhibitors cross-reaction on the basis of kinase ATP cavity similarities: a study using PKSIM protein similarity score.ErG: 2D pharmacophore descriptions for scaffold hopping.On the art of compiling and using 'drug-like' chemical fragment spaces.Solvation enthalpies as descriptors of structure--in vitro percutaneous permeation relationship of benzoxazinones regioisomers.Synthesis and biological evaluation of novel (4 or 5-aryl)pyrazolyl-indoles as inhibitors of interleukin-2 inducible T-cell kinase (ITK).Rational design of a new C-myristylamido peptide exerting potent and selective PKC inhibitory activitySequence and structural homologies between M. tuberculosis chaperonin 10 and the MHC class I/II peptide binding cleftMS-WHIM, new 3D theoretical descriptors derived from molecular surface properties: a comparative 3D QSAR study in a series of steroidsA new rational hypothesis for the pharmacophore of the active metabolite of leflunomide, a potent immunosuppressive drugGlobal 3D-QSAR methods: MS-WHIM and autocorrelationThe interaction of myristylated peptides with the catalytic domain of protein kinase C revealed by their sequence palindromy and the identification of a myristyl binding siteA knowledge-based weighting approach to ligand-based virtual screening
P50
Q33475687-4402B800-9A3C-49F8-B0AA-DE9F7C9375FAQ34015778-4867FE23-74C8-449B-BFA8-E69A2ED73387Q36380711-2DC58680-5366-4900-88BF-A730BAE9968EQ43451646-DEA93723-48BC-4D82-B34F-44BFFFB97BFEQ47604123-E528C518-9E3D-4356-AB4B-364A4EC34583Q50296051-408DE14A-D7F2-43F9-88E2-122B5B8C9A5EQ51631484-F3B558B5-EEE6-4DF0-AEDC-5D27B574D9A9Q51869169-CF79F112-9F82-46E2-9DFD-4B60C9963892Q52069729-150FB4D2-325F-48C1-A7C7-B0868BB236E9Q54674245-4F95564D-D77E-4054-89E2-C0D01321FF52Q71692163-CF021F5D-2E53-431D-AF5D-989F1EAFA015Q72307715-377A565D-F35E-4879-9B0B-0754237342C9Q73315115-13155C8B-88E6-4451-A942-F814CCC71093Q73477682-9E83FE13-C2D0-4FB0-B4D1-02849163B98CQ73652694-B607E636-CC98-495D-B6B5-F28F46507659Q77492383-A2F6B56B-1B74-4E39-866A-C84CA51A3397Q82962454-6588C4D4-5E13-4224-BBDE-F725D130F9A1
P50
description
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Andrea Zaliani
@ast
Andrea Zaliani
@en
Andrea Zaliani
@es
Andrea Zaliani
@nl
type
label
Andrea Zaliani
@ast
Andrea Zaliani
@en
Andrea Zaliani
@es
Andrea Zaliani
@nl
prefLabel
Andrea Zaliani
@ast
Andrea Zaliani
@en
Andrea Zaliani
@es
Andrea Zaliani
@nl
P106
P31
P496
0000-0002-1740-8390